Abstract
Large molecule drug markets have emerged as a key contender for R&D investment
where small molecule pipelines are seeing growing generic pressures and
reduced new drug approvals. Biotechnology companies, with a strong pipeline
presence of large molecule biologic drugs, have benefited from strengthened
market positioning. However, with drug failure rates for this immature
industry high existing large molecule delivery is focused on the established
parenteral route. Emerging drug delivery technologies are looking to improve
measures of safety, efficacy, convenience and compliance in both new and
existing drug candidates and products. For marketed products reformulations
with new delivery technologies will extend the period of patent protection. In
chronic diseases where patient compliance surrounding dosing strategies and
ease of administration are key, limitations on further market growth these new
formulas will be key to boosting volume sales of large molecule products. In
R&D pipelines novel application of delivery technologies will expose new
methods to reformulate failed or discontinued drugs and mask their unfavorable
effects, expanding the market of potential drug candidates.
| 
View Cart
